MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2016

Jul 26, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SYNTA PHARMACEUTICALS CORP (MDGL)
CIK: 0001157601
Period of Report: 2016-07-22

Reporting Person: CRAVES FRED B (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-07-22	Common Stock	A	296067	—	Acquired	296067	Direct
2016-07-22	Common Stock	A	5538474	—	Acquired	5538474	Indirect
2016-07-22	Common Stock	A	119380	—	Acquired	119380	Indirect

Footnotes

F1: Shares issued relate to the exchange of shares of Madrigal Pharmaceuticals, Inc. (as a private company) for shares of Synta Pharmaceuticals Corp. per Synta's agreement to acquire Madrigal, dated April 13, 2016. After the completion of the Merger, Synta Pharmaceuticals Corp. changed its name to Madrigal Pharmaceuticals, Inc.

F2: Dr. Craves disclaims beneficial ownership of these securities owned by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Fund IV's general partner, Bay City Capital Management IV LLC.

F3: Dr. Craves disclaims beneficial ownership of these securities owned by Co-Investment, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Co-Investment's general partner, Bay City Capital Management IV LLC.